State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, China CDC 100 Ying Xin Jie, Xuan Wu Qu, Beijing 100052, China.
Vaccine. 2010 Jun 11;28(26):4294-300. doi: 10.1016/j.vaccine.2010.04.025. Epub 2010 Apr 28.
A safe and effective hantavirus vaccine is highly desirable since hantaviruses are distributed worldwide and cause an acute and often fatal disease (hemorrhagic fever with renal syndrome, HFRS). Virus-like particles (VLPs) displaying functional viral proteins could provide effective vaccines against a few viruses, but their ability to induce hantavirus-specific immune response has not been adequately investigated. To measure the immunogenicity of Hantaan virus-like particles (HTN-VLPs) vaccine, we generated recombinant HTN-VLPs by co-expressing Hantaan virus nucleocapsid (N) protein and glycoproteins (Gn and Gc) in Chinese hamster ovary (CHO) cells. We compared intramuscular versus subcutaneous administration of HTN-VLPs for the ability to induce specific immune response against Hantaan virus infection. Mice that received both intramuscular and subcutaneous immunizations of HTN-VLPs were sufficiently stimulated specific antibody response against Hantaan virus N protein and glycoproteins, which was comparable to Chinese commercial inactivated bivalent hantaviruses vaccine. Moreover, vaccination with HTN-VLPs also resulted in the induction of higher levels of specific cellular response to N protein than that of inactivated vaccine. Our results provide an important insight towards the development of hantaviruses-like particles as a potential candidate vaccine for the control and prevention of hantaviruses infection.
一种安全有效的汉坦病毒疫苗是非常需要的,因为汉坦病毒分布在全球范围内,会引起急性且常常致命的疾病(肾综合征出血热,HFRS)。展示功能性病毒蛋白的病毒样颗粒(VLPs)可以为一些病毒提供有效的疫苗,但它们诱导汉坦病毒特异性免疫反应的能力尚未得到充分研究。为了测量汉坦病毒样颗粒(HTN-VLPs)疫苗的免疫原性,我们通过在中国仓鼠卵巢(CHO)细胞中共表达汉坦病毒核衣壳(N)蛋白和糖蛋白(Gn 和 Gc)来产生重组 HTN-VLPs。我们比较了 HTN-VLPs 的肌内和皮下给药方式,以评估其诱导针对汉坦病毒感染的特异性免疫反应的能力。接受 HTN-VLPs 肌内和皮下免疫的小鼠对汉坦病毒 N 蛋白和糖蛋白产生了足够的特异性抗体反应,这与中国商业的双价灭活汉坦病毒疫苗相当。此外,HTN-VLPs 疫苗接种还导致针对 N 蛋白的特异性细胞反应水平高于灭活疫苗。我们的研究结果为开发汉坦病毒样颗粒作为控制和预防汉坦病毒感染的潜在候选疫苗提供了重要的见解。